Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2024-12-17 Major Shareholding Noti…
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2024-12-17 English
DFAN14A
Proxy Solicitation & Information Statement
2024-12-16 English
Remuneration Information 2024
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to the solicitation of shareholder votes for the company's annual meeting. It includes detailed information about the proxy solicitation, the board members up for election, and encourages shareholders to vote. It references the definitive proxy statement filed earlier and provides additional materials related to the annual meeting. The document is not the proxy statement itself but additional materials related to it. Given the form type DEFA14A and the content focusing on proxy solicitation and voting materials, the appropriate classification is Remuneration Information (DEF 14A), which covers reports detailing compensation and proxy-related information for executives and directors. The document length and detail confirm it is not a brief announcement but substantive proxy-related material.
2024-12-16 English
DFAN14A
Proxy Solicitation & Information Statement
2024-12-13 English
Proxy Solicitation & Information Statement 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing with the SEC, which is a proxy statement related to the solicitation of shareholder votes for the company's 2024 Annual Meeting. It includes detailed information about the board nominees, voting recommendations, and proxy solicitation materials. The document references the definitive proxy statement filed earlier and urges shareholders to vote for the incumbent board members. It does not contain financial statements or earnings data but focuses on governance and shareholder voting matters. The presence of the term 'Proxy Statement' and the detailed discussion about board members and voting strongly indicates this is a Proxy Solicitation & Information Statement filing. Therefore, the correct classification is DEF 14A (Remuneration Information) or PSI (Proxy Solicitation & Information Statement). Since this document is a Schedule 14A proxy statement with solicitation materials, the appropriate code is PSI.
2024-12-12 English
DFAN14A
Proxy Solicitation & Information Statement
2024-12-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.